Scotiabank slashes price target on Tempest Therapeutics Inc [TPST] – find out why.

Tempest Therapeutics Inc [NASDAQ: TPST] closed the trading session at $1.10.

The stocks have a year to date performance of -75.00 percent and weekly performance of 4.76 percent. The stock has been moved at -68.30 percent over the last six months. The stock has performed -21.43 percent around the most recent 30 days and changed -38.20 percent over the most recent 3-months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

If compared to the average trading volume of 4.41M shares, TPST reached to a volume of 4692778 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Tempest Therapeutics Inc [TPST]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TPST shares is $19.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TPST stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Scotiabank have made an estimate for Tempest Therapeutics Inc shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on March 14, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on February 08, 2024, representing the official price target for Tempest Therapeutics Inc stock.

The Average True Range (ATR) for Tempest Therapeutics Inc is set at 0.13 The Price to Book ratio for the last quarter was 1.59, with the Price to Cash per share for the same quarter was set at 1.23.

TPST stock trade performance evaluation

Tempest Therapeutics Inc [TPST] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.76. With this latest performance, TPST shares dropped by -21.43% in over the last four-week period, additionally sinking by -68.30% over the last 6 months – not to mention a drop of -73.93% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TPST stock in for the last two-week period is set at 42.06, with the RSI for the last a single of trading hit 43.02, and the three-weeks RSI is set at 41.77 for Tempest Therapeutics Inc [TPST]. The present Moving Average for the last 50 days of trading for this stock 1.2797, while it was recorded at 1.0860 for the last single week of trading, and 2.6654 for the last 200 days.

Tempest Therapeutics Inc [TPST]: An insightful look at the core fundamentals

Tempest Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.17 and a Current Ratio set at 2.17.

Earnings per share (EPS) analysis for Tempest Therapeutics Inc [TPST] stock

With the latest financial reports released by the company, Tempest Therapeutics Inc posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at -0.57/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TPST.

Tempest Therapeutics Inc [TPST]: Institutional Ownership

There are presently around $22.43%, or 22.49%% of TPST stock, in the hands of institutional investors. The top three institutional holders of TPST stocks are: BLACKROCK INC. with ownership of 0.55 million shares, which is approximately 2.4747%. FMR LLC, holding 0.43 million shares of the stock with an approximate value of $$0.95 million in TPST stocks shares; and FMR LLC, currently with $$0.39 million in TPST stock with ownership which is approximately 0.7924%.